Pembrolizumab for cancer treatment based on biomarker regardless of tumour type given priority review in the US
In the US, pembrolizumab as monotherapy will be reviewed via an accelerated basis for use in adult and paediatric unresectable or metastatic solid tumours with high tumour mutational burden, who have progressed following prior treatment and who have no satisfactory alternative.
Source:
Biospace Inc.